Nektar Therapeutics (NKTR) Other Working Capital Changes (2010 - 2026)

Nektar Therapeutics' Other Working Capital Changes history runs 7 years deep, the most recent figure standing at -$605000.0 for Q1 2021.

• On a quarterly basis, Other Working Capital Changes rose 75.9% year-over-year to -$605000.0 in Q1 2021; TTM through Dec 2021 was -$605000.0, a 89.03% increase from a year earlier, with the FY2022 full-year figure at -$1.1 million, down 75.21% from the prior year.
• Other Working Capital Changes retreated to -$605000.0 in Q1 2021 per NKTR's latest filing, from -$446000.0 in the prior quarter.
• Across five years, Other Working Capital Changes topped out at $9.9 million in Q4 2025 and bottomed at -$5.6 million in Q1 2023.
• The 5-year median for Other Working Capital Changes is $618000.0 (2025), against an average of $482235.3.
• Across the five-year window, Other Working Capital Changes sank 61.36% in 2019 and soared 93.72% in 2020, its largest moves.
• Year by year, Other Working Capital Changes stood at -$43.7 million in 2017, then jumped by 89.94% to -$4.4 million in 2018, then slumped by 61.36% to -$7.1 million in 2019, then surged by 93.72% to -$446000.0 in 2020, then tumbled by 35.65% to -$605000.0 in 2021.
• Per Business Quant, the three latest NKTR Other Working Capital Changes figures stand at -$605000.0 (Q1 2021), -$446000.0 (Q4 2020), and -$1.3 million (Q3 2020).